The Efficacy of Recombinant Human Follicle Stimulating Hormone (rhFSH) in Human IVF-ET Program.
- Author:
Kuk Sun HAN
;
Hong Bok LEE
;
In Ok SONG
;
Yong Seog PARK
;
Hye Kyung BYUN
;
Jin Hyun JUN
;
Mi Kyoung KOONG
- Publication Type:Original Article
- Keywords:
Recombinant human follicle stimulating hormone (rFSH);
Urinary gonadotropin (uFSH);
IVF-ET;
Total dose of gonadotropin;
Pregnancy rate
- MeSH:
Animals;
Cell Line;
Cricetinae;
Cricetulus;
Embryo Transfer;
Embryonic Structures;
Estradiol;
Female;
Follicle Stimulating Hormone, Human*;
Gonadotropins;
Humans*;
Infertility;
Oocytes;
Ovary;
Pregnancy Rate;
Social Sciences
- From:Korean Journal of Fertility and Sterility
2002;29(1):45-56
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVES: Recently, recombinant FSH (rFSH) has been manufactured using a Chinese hamster ovary cell line transfected with the gene encoding human FSH. Both rFSH and urinary gonadotropin (uFSH) could be used for controlled ovarian hyperstimulation (COH). However, uFSH implies a number of disadvantages, such as batch-to-batch inconsistency, no absolute source control, dependence on large amounts of urine, low specific activity, and low purity. The purpose of this study was to evaluate the efficacy of rFSH in human IVF-ET program. MATERIALS AND METHODS: A total of 508 infertile women was enrolled in this study. They are classified into rFSH group (n=177) or uFSH group (n=331), and all of them were matched by age and cause of infertility in same period. The Puregon(R) (Organon, Holland) was used as rFSH, and the Metrodin-HP(R) (Serono, Switzeland) and Humegon(R) (Organon, Holland) was used as uFSH. We subdivided the patients into three age groups. The outcomes of IVF-ET program were analyzed using the statistical package for social sciences (SPSS). RESULTS: There was no significant differences in the level of estradiol on hCG injection day, the numbers of retrieved oocytes, matured oocytes, fertilized oocytes, transferred embryos, frozen embryos between the two groups. The total dose (IU) of gonadotropin for COH was significantly lower in the rFSH group compared to uFSH group (1339+/-5491.1 vs 2527.8+/-1075.2 IU, p<0.001). Clinical pregnancy rate per embryo transfer in the rFSH group showed increasing tendency, compared to the uFSH group, but there was no statistical significance (35.2% vs 29.3%). Our results demonstrated that the relative efficiency of rFSH compared with uFSH is higher in older patients. CONCLUSIONS: The ovarian stimulatory effect and clinical outcome of recombinant FSH was similar to that of the urinary gonadotropin. The IVF-ET cycles with significantly lower dose of gonadotropin in rFSH group showed comparable results. Therefore, we suggest that recombinant FSH is more potent and effective than urinary gonadotropin.
